The observed overexpression of Fancd2 and Xrcc6 in myeloma-like plasma cell tumors from IL6MYC mice established an interesting parallel to human MM, in which the Fanconi anemia/breast cancer (FA/BRCA) DNA damage repair pathway has been identified as an important effector mechanism of myeloma cell responses to replicative stress induced by DNA alkylating agents, such as the widely used myeloma drug melphalan [33]. This evidence concerns the gene FANCD2 and breast cancer.